We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Small Pharma Inc | TSXV:DMT | TSX Venture | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.15 | 0.19 | 0.19 | 0 | 00:00:00 |
“As we have seen over the past 18 months, drug development is hard. The good news is many of the companies presenting over the two-day event have shown tremendous clinical progress. I would encourage investors to take a traditional pharma or biotech view of this space and practice patience, do the proper diligence, and the rewards will be tremendous,” said Lewis Goldberg, Managing Partner and Founder of KCSA’s Psychedelics Practice. “Drug development for mental health care takes time, focus, and is capital intensive. The potential returns remain as dramatic as ever, it’s the investors who – to steal a line from Michael Pollan – need to change their minds.”
REGISTER NOW AT: https://bit.ly/3rFbSuZIt is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations and schedule 1x1 meetings.
April 27th Agenda:
EasternTime (ET) | Presentation | Ticker(s) |
9:30 AM | HMNC Brain Health | Private |
10:00 AM | Field Trip Health Ltd. | NASDAQ: FTRP | TSX: FTRP |
10:30 AM | Psyched Wellness Ltd. | OTCQB: PSYCF | CSE: PSYC |
11:00 AM | Enveric Biosciences | NASDAQ: ENVB |
11:30 AM | Lobe Sciences Ltd. | OTCQB: LOBEF | CSE: LOBE |
12:00 PM | Ninnion Therapeutics | Private |
12:30 PM | PsyBio Therapeutics | OTCQB: PSYBF | TSXV: PSYB |
1:00 PM | Numinus Wellness | OTCQX: NUMIF | TSX: NUMI |
April 28th Agenda:
EasternTime (ET) | Presentation | Ticker(s) |
9:30 AM | Small Pharma Inc. | OTCQB: DMTTF | TSXV: DMT |
10:00 AM | Mindset Pharma Inc. | OTCQB: MSSTF | CSE: MSET |
10:30 AM | Gilgamesh Pharma | Private |
11:00 AM | Cybin Inc. | NYSE AMEX: CYBN | NEO: CYBN |
11:30 AM | Filament Health Corp. | OTCQB: FLHLF | NEO: FH |
12:00 PM | Awaken Life Sciences Corp. | OTCQB: AWKNF | NEO: AWKN |
To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
About KCSA Strategic CommunicationsKCSA is a fully integrated communications agency specializing in public relations, investor relations and social media, with expertise in financial and professional services, technology, healthcare, digital media and cannabis. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm's clients are its best references. For more information, please visit www.kcsa.com.
Media Contact: OTC Markets Group Inc. +1 (212) 896-4428, media@otcmarkets.com
Virtual Investor Conferences Contact:John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@otcmarkets.com
KCSA Contact:Allison Soss / Tim Regan KCSA Strategic Communications conference@kcsa.com
1 Year Small Pharma Chart |
1 Month Small Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions